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Background/introduction
The delivery of systemically administered drugs and
genes to the CNS is hindered by both the blood-brain
barrier (BBB), which limits transport from the blood-
stream to the brain to only a few privileged molecules,
and the nanoporous electrostatically charged tissue
space, denoted here as the “brain tissue barrier” (BTB).
Our group engineers targeted drug and gene delivery
approaches, capable of overcoming both of these physi-
cal barriers, for the treatment of brain tumors and neu-
rodegenerative diseases. We focus on nanoparticle (NP)
delivery systems, as they offer the potential for enhanced
transfection efficiencies and controlled-drug release.
Methods
To deliver drug- and gene-bearing NPs across the BBB,
we use focused ultrasound (FUS) and contrast agent
microbubbles (MBs). FUS may be applied using either
MR-guidance or with a simple table-top system. We and
others have shown that activating MBs with FUS yields
safe and transient BBB opening in the FUS focal zone.
Technologies for overcoming the BTB center on coating
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the drug and gene bearing NPs with an extremely dense
brush layer of polyethylene glycol (PEG). NPs are
injected at the time of BBB opening to permit their
delivery to the CNS.
Results and conclusions
Drug Bearing NP Delivery – PEG-coated polystyrene
(PS) tracer NPs (60 nm diameter) and biodegradable
polylactide-co-glycolide (PLGA) NPs (75 nm) were engi-
neered to penetrate brain tissue and then delivered
across the BBB in rats using 1 MHz FUS. NPs were
delivered to endothelium and as “clouds” to brain tissue.
PS-NP delivery through the brain continued over 24
hours, yielding enhancements of cloud size and intensity
(Figure 1A). FUS at 0.6 MPa delivered a larger fraction
of PS-NP to the interstitial space (Figure 1D) and
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increased PS-NP coverage area (Figure 1B). The percen-
tage of PS-NP+ vessels producing clouds was increased
(P<0.05) to 50% at 0.6 MPa (Figure 1C). The higher US
pressure produced a significant 4.6-fold increase in large
(i.e. >200 μm2) PS-NP clouds. Focal spot intensity on
MRI predicted the number of PS-NP clouds (Figure 1E).
We also verified that BBB opening with MBs and FUS
at 0.6 MPa can be used to substantially increase 60 nm
PS-NP delivery to intracranial 9L rat tumors.
Gene Bearing NP Delivery — We used a blend of non-
PEGylated and highly PEGylated polymers at an optimized
ratio to engineer brain-penetrating DNA NPs with a poly-
ethylenemine (PEI) core polymer. We delivered PEI-NPs
(~50 nm in diameter) carrying either luciferase or
mCherry plasmid DNA (driven by the unmethylated
CpG-free b-actin promoter) across the BBB in rats using
MR-guided FUS and MBs. Robust luciferase transgene
expression, corresponding to a single focal site of FUS
exposure, was visible (Figure 2A), and the intensity of gene
expression was correlated with PEI-NP concentration
(Figure 2B). After delivering mCherry PEI-NPs across the
BBB with FUS and MBs, we immunochemically detected
mCherry in both glial cells (GFAP, red) and neuronal cell
nuclei (NeuN, green) (Figure 2C). mCherry expression
was homogeneously distributed throughout the sonicated
area (Figure 2C), demonstrating the benefit of combining
FUS-mediated delivery across the BBB with brain-pene-
trating NPs. We believe these studies represent the first
evidence for brain transfection via the delivery of a non-
viral gene NP across the BBB with FUS. Going forward,
this approach may be used to deliver genes for neuro-
trophic factors for the treatment of neurodegenerative
diseases.
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